Mitoxantrone and Paclitaxel Combination Chemotherapy in Metastatic Breast Cancer

REFERENCES

• Harris J. R., Morrow M., Bonadonna G. Cancer of the Breast. Cancer Principles and Practice of Oncology, V. T. De Vita, Jr., S. Hellman, S. A. Rosenberg. 4th Ed., J.P. Lippincott Company, Philadelphia 1993; 1265–1331
   Google Scholar
• Fossati R., Confalonieri C., Torri V., Ghislandi E., Penna A., Pistotti V., Tinazzi A., Liberati A. Cytotoxic and Hormonal Treatment for Metastatic Breast Cancer: A Systematic Review of Published Randomized Trials Involving 31,510 Women. J. Clin. Oncol. 1998; 16: 3439–3460
   PubMed Web of Science ®Google Scholar
• Holmes F. A., Walters R. S., Theriault R. L., Forman A. D., Newton L. K., Raber M. N., Buzdar A. U., Frye D. K., Hortobagyi G. N. Phase II Trial of Taxol: An Active Drug in the Treatment of Metastatic Breast Cancer. J. Natl. Cancer Inst. 1991; 83: 1797–1805
   PubMed Web of Science ®Google Scholar
• Seidman A. D., Tiersten A., Hudis C., Gollub M., Barrett S., Yao T. J., Lepore J., Gilewski T., Currie V., Crown J. Phase II Trial of Paclitaxel by Three-Hour Infusion as Salvage Chemotherapy for Metastatic Breast Cancer. J. Clin. Oncol. 1995; 13: 2575–2581
   PubMed Web of Science ®Google Scholar
• Seidman A. D., Hudis C. A., Raptis G., Baselga J., Fennelly D., Norton L. Paclitaxel for Breast Cancer: The Memorial Sloan-Kettering Cancer Center Experience. Oncology 1997; 3(suppl 2)20–28
   Google Scholar
• Hortibagyi G. N. Paclitaxel-Based Combination Chemotherapy for Breast Cancer. Oncology 1997; 11(suppl 2)29–37
   Google Scholar
• Gianni L., Munzone E., Capri G., Fulfaro F., Tarenzi E. M., Villani F., Spreafico C., Laffranchi A., Caraceni A., Martini C., Stefanelli M., Valagussa P., Bonadonna G. Paclitaxel by 3-Hour Infusion in Combination with Bolus Doxorubicin in Women with Untreated Metastatic Breast Cancer: High Antitumor Efficacy and Cardiac Effects in a Dose-Finding and Sequence-Finding Study. J. Clin. Oncol. 1995; 13: 2688–2699
   PubMed Web of Science ®Google Scholar
• Gianni L. Paclitaxel Plus Doxorubicin in Metastatic Breast Cancer: The Milan Experience. Oncology 1998; 12: 13–15
   PubMed Web of Science ®Google Scholar
• Gehl J., Boesgaard M., Paaske T., Jensen B. V., Dombernowsky P. Combined Doxorubicin and Paclitaxel in Advanced Breast Cancer: Effective and Cardiotoxic. Ann. Oncol. 1996; 7: 687–693
   PubMed Web of Science ®Google Scholar
• Dombernowsky P., Gehl J., Boesgaard M., Paaske T., Jensen B. V. Doxorubicin and Paclitaxel, a Highly Active Combination in the Treatment of Metastatic Breast Cancer. Semin. Oncol. 1996; 23(suppl 11)23–27
   PubMedGoogle Scholar
• Dombernowsky P., Boesgaard M., Andersen E., Jensen B. V. Doxorubicin Plus Paclitaxel in Advanced Breast Cancer. Semin. Oncol. 1997; 24(suppl 17)S17-15–S17-18
   Google Scholar
• Dieras V. Taxanes in Combination with Doxorubicin in the Treatment of Metastatic Breast Cancer. Semin. Oncol. 1998; 25(suppl 12)18–22
   PubMedGoogle Scholar
• Stuart-Harris R. C., Smith I. E. Mitoxantrone: A Phase II Study in the Treatment of Patients with Advanced Breast Carcinoma and Other Solid Tumours. Cancer Chemother. Pharmacol. 1982; 8: 179–182
   PubMed Web of Science ®Google Scholar
• Yap H. Y., Blumenschein G. R., Schell F. C. Dihydroxyanthracenedoine: A Promising New Drug in the Treatment of Metastatic Breast Cancer. Ann. Intern. Med. 1981; 95: 694–697
   PubMed Web of Science ®Google Scholar
• Henderson I. C., Allegra J. C., Woodcock T., Wolff S., Bryan S., Cartwright K., Dukart G., Henry D. Randomized Clinical Trial Comparing Mitoxantrone with Doxorubicin in Previously Treated Patients with Metastatic Breast Cancer. J. Clin. Oncol. 1989; 7: 560–567
   PubMed Web of Science ®Google Scholar
• Levin M., Pandya K. J., Khandekar J. D., Horton J., Glick J. H., Bennett J. M., Muggia F. M., Falkson G. Phase II Study of Mitoxantrone in Advanced Breast Cancer: An Eastern Cooperative Oncology Group Pilot Study. Cancer Treat. Rep. 1984; 68: 1511–1512
   PubMedGoogle Scholar
• Hainsworth J. D., Andrews M. B., Johnson D. H., Greco F. A. Mitoxantrone, Fluorouracil, and High-Dose Leucovorin: An Effective, Well Tolerated Regimen for Metastatic Breast Cancer. J. Clin. Oncol. 1991; 9: 1731–1733
   PubMed Web of Science ®Google Scholar
• Hainsworth J. D. Mitoxantrone, 5-Fluorouracil and High-Dose Leucovorin (NFL) in the Treatment of Metastatic Breast Cancer: Randomized Comparison to Cyclophosphamide, Methotrexate and 5-Fluorouracil (CMF) and Attempts to Improve Efficacy by Adding Paclitaxel. Eur. J. Cancer Care (Engl.) 1997; 6(suppl 4)4–9
   PubMedGoogle Scholar
• Ingle J. N., Kardinal C. F., Suman V. J., Veeder M. H., Schaefer P. L., Kirschling R. J., Mailliard J. A. Mitoxantrone Dose Augmentation Utilizing Filgrastim Support in Combination with Fixed-Dose 5-Fluorouracil and Leucovorin in Women with Metastatic Breast Cancer. Breast Cancer Res. Treat. 1997; 43: 193–200
   PubMed Web of Science ®Google Scholar
• Hainsworth J. D., Jones S. E., Mennel R. G., Blum J. L., Greco F. A. Paclitaxel with Mitoxantrone, Fluorouracil, and High-Dose Leucovorin in the Treatment of Metastatic Breast Cancer: A Phase II Trial. J. Clin. Oncol. 1996; 14: 1611–1616
   PubMed Web of Science ®Google Scholar
• Panagos G. E. for the South-Central Hellenic Oncology Group. Treatment of Advanced and Relapsing Breast Cancer with a Combination of Paclitaxel and Mitoxantrone. Semin. Oncol., 24(suppl 3)S3-17–S3-21
   Google Scholar
• Fleming G. F., Janisch L., Vogelzang N. J., Vokes E. E., Ratain M. J. Phase I Study of Escalating Doses of Mitoxantrone and Paclitaxel with Granulocyte-Macrophage Colony Stimulating Factor Support. Cancer 1996; 77: 2308–2312
   PubMed Web of Science ®Google Scholar
• Harvey J., Cantrell J., Campbell M., Cartmell A., Urba W., Rubin A., Ghalie R., Modiano M., Schuster M. Mitoxantrone + Paclitaxel (NT) vs. Paclitaxel (T) Alone for Metastatic Breast Cancer. Proc. Am. Soc. Clin. Oncol. 1997; 16: 171a, (abstract 601)
   Google Scholar
• Ajani J. A., Welch S. R., Raber M. N., Fields W. S., Krakoff I. H. Comprehensive Criteria for Assessing Therapy-Induced Toxicity. Cancer Invest. 1990; 8: 147–159
   PubMed Web of Science ®Google Scholar
• Hayward J. L., Carbone P. P., Heuson J. C., Kumaoka S., Segaloff A., Rubens R. D. Assessment of Response to Therapy in Advanced Breast Cancer. A Project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Eur. J. Cancer 1997; 13: 89–94
   Google Scholar
• Schipper H., Clinch J., McMurray A., Levitt M. Measuring the Quality of Life in Cancer Patients: The Functional Living Index-Cancer: Development and Validation. J. Clin. Oncol. 1984; 2: 472–483
   PubMed Web of Science ®Google Scholar
• Miller K. D., Sledge G. W. Taxanes in the Treatment of Breast Cancer: A Prodigy Comes of Age. Cancer Invest. 1999; 17: 121–136
   PubMed Web of Science ®Google Scholar
• Hortobagyi G. N. Treatment of Breast Cancer. N. Engl. J. Med. 1998; 339: 974–984
   PubMed Web of Science ®Google Scholar